For type 2 diabetes mellitus. ANDA 209882, held by Laurus. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 209882 (Metformin Hydrochloride), held by Laurus, was first approved by FDA on Aug 27, 2018, with 3 approved supplements and 0 published complete response letters.
Metformin hydrochloride tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 27, 2018 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 11, 2026 | Supplement 21Labeling · Standard review | Approved | None posted |
| May 17, 2021 | Supplement 6Manufacturing | Approved | None posted |
| Aug 27, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters